Company Research Report: Genialis, Inc.
Company Overview
Name:
Genialis, Inc.
Mission:
Genialis, Inc. is focused on reimagining biomarkers with RNA and AI to achieve precision oncology for every patient. They envision a world where precision medicine delivers the best possible outcomes for patients, families, and their communities.
Founded:
2015
Founders:
No information is available.
Key People:
- Rafael Rosengarten, Ph.D. - Chief Executive Officer and Co-founder.
- Miha Štajdohar, Ph.D. - Chief Technology Officer and Co-founder.
- Tjaša Krisper Kutin - Chief Operating Officer.
- Luka Ausec, Ph.D. - Chief Discovery Officer.
- Krista McKerracher - Chairperson of the Board.
Headquarters:
68 Harrison Ave #605, PMB 29417, Boston, MA 02111
Number of Employees:
Genialis employs between 11-50 individuals.
Revenue:
No information is available.
What is the company known for:
Genialis is known as the RNA Biomarker company, specializing in the development and validation of RNA-based biomarkers to predict patient responses and guide treatment decisions for oncology therapies.
Products
Genialis™ krasID
High-Level Description:
- Genialis™ krasID is an innovative patient classifier designed to predict and monitor drug response from preclinical models to real-world patient cohorts. It is both necessary and sufficient to predict tumor response and clinical benefit to KRAS-targeted therapeutics.
Key Features:
- Predicts clinical benefit of KRAS inhibitors with over 84% precision.
- Demonstrates >94% accuracy across various KRAS inhibitors in preclinical models.
- Enhances translational package and differentiates against competing KRAS inhibitors.
- Identifies patients most likely to respond to KRAS inhibitors with >80% accuracy.
- Monitors and optimizes time on therapy by over 2.5x.
ResponderID™
High-Level Description:
- ResponderID™ is a framework for biomarker discovery by modeling complex disease biology using algorithms that predict response to therapies.
Key Features:
- Capable of developing biomarkers for drugs by modeling disease biology.
- Adheres to FDA's Good Machine Learning Practice guidelines.
- Provides comprehensive picture of each patient’s disease.
- Stratifies which patients are likely to respond to a particular drug.
Genialis Expressions
High-Level Description:
- Genialis Expressions is software enabling machine-learning driven biomarker discovery by aggregating consistently analyzed and annotated data.
Key Features:
- Built on FAIR data management principles for reproducible, scalable, and secure analyses.
- Validated bioinformatics protocols and data flywheel technology.
- Supports high throughput genomic, transcriptomic, and epigenomic sequencing data analysis.
- Offers deployment in private or public cloud infrastructure.
Recent Developments
Recent Achievements:
- Biotech Innovation Award Finalist: Genialis was named a finalist for the Biotech Innovation Award at Biotech Week Boston for advances in RNA- and AI-based diagnostic algorithms.
New Products Launched:
No new products launched information is available.
New Features Added to Existing Products:
- Genialis™ krasID: The precision of predicting patient response to KRAS inhibitors was demonstrated to be >84% at the AACR 2024 Annual Meeting.
New Partnerships:
- Pancreatic Cancer Action Network (PanCAN): Partnership to progress KRAS Diagnostics.
- Cancer Research Horizons: Collaboration to develop AI-driven patient classifiers.
- Debiopharm: Biomarker Discovery Collaboration.
Conferences and Events:
- Participation in various industry events including the 14th World Clinical Biomarkers & Companion Diagnostics Summit, PanCAN Scientific Summit 2024, AACR Special Conference: Advances in Pancreatic Cancer Research, and the 6th Annual RAS-Targeted Drug Development Summit.
Conclusion
Genialis, Inc., with its mission to enhance precision oncology through RNA biomarkers and AI, stands out for its innovative genetic analysis technologies. Key products like Genialis™ krasID and ResponderID™ highlight its capacity to significantly impact clinical decision-making and drug development in oncology. Their recent accolades and evolving partnerships underscore their growing influence in the biotech sector.
For further exploration and collaborations, Genialis seeks proactive engagement with stakeholders across Pharma, Biopharma, Diagnostics, and Research Centers.
